"What we saw was it that there were a significant number of patients that did change their management based on the findings. Of those patients, 88% of them changed because of a positive test," says Benjamin H. Lowentritt, MD, FACS.
In this video, Benjamin H. Lowentritt, MD, FACS, highlights the background and key findings from the study, “Impact of 18F-flotufolastat PET on management of patients with recurrent prostate cancer: Data from the SPOTLIGHT study,” which was presented at the 2024 Genitourinary Cancers Symposium in San Francisco, California. Lowentritt is a urologist at Chesapeake Urology in Towson, Maryland.
This is also data that came from the SPOTLIGHT trial, looking at biochemical recurrence in the use of the F18 radiohybrid PSMA agent as an imaging agent. Specifically what we're looking at here, which is a really important thing to know, is when we have follow-up data, can you tell if this was impactful to changing any decisions. What we saw was it that there were a significant number of patients that did change their management based on the findings. Of those patients, 88% of them changed because of a positive test. So, maybe from either systemic therapy to more targeted therapy, or potentially from a more targeted therapy to a more systemic therapy if there was more disease than was anticipated. There were about 12% of the patients that changed that were due to a negative test. So, maybe went from systemic therapy to more targeted salvage, or potentially just to observation and avoid any therapy at all since there was not a demonstrable lesion. It's really important to have this data and to know that it is impacting what patients and their physicians are deciding to do.
This transcription has been edited for clarity.